Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients
This study has been completed.
Study NCT00616551 Information provided by Ambrilia Biopharma, Inc.
First Received on February 4, 2008. Last Updated on October 7, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Bone Diseases, Endocrine
Central Nervous System Diseases
Endocrine System Diseases
Nervous System Diseases
Interventions listed in this trial
C2L-OCT-01 PR, 30 mg
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Antineoplastic Agents, Hormonal
Sponsors listed in this trial
Ambrilia Biopharma, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers